Marc Gittelman

THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER

Kevin M. Tomera, Marc Gittelman, W.M. Moseley et al. · The Journal of Urology · 2001 · 103 citations

Medicine, Endocrinology, Pharmacology +10

THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER

Kevin M. Tomera, Donald M. Gleason, Marc Gittelman et al. · The Journal of Urology · 2001 · 99 citations

Medicine, Endocrinology, Pharmacology +10

Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist: an investigation of warning time in patients with OAB

Norman R. Zinner, Jacques G. Susset, Marc Gittelman et al. · International Journal of Clinical Practice · 2005 · 62 citations

Medicine, Pharmacology, Pharmacotherapy +17

Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer

Evan Y. Yu, Robert H. Getzenberg, Christopher C. Coss et al. · European Urology · 2014 · 19 citations

Medicine, Endocrinology, Urology +14

Efficacy and Safety of a New Topical Testosterone Replacement Gel Therapy for the Treatment of Male Hypogonadism

Glenn R. Cunningham, Laurence Belkoff, Gerald Brock et al. · Endocrine Practice · 2017 · 16 citations

Medicine, Endocrinology, Pharmacotherapy +12